Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

New NCCN Guidelines published for Vulvar Cancer

It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the disease[i]. In order to provide comprehensive, up-to-date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer Network, an alliance of 26 of the nation's leading cancer centers, has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer.

27 Jan 2016

Velano Vascular obtains FDA clearance for modified version of novel blood draw device

Velano Vascular, a medical technology company transforming and enhancing the care experience for hospitalized patients and their practitioners, announced today that the company received U.S. Food and Drug Administration clearance for a modified version of its novel, needle-free blood draw device.

27 Jan 2016

DNA imprinting defect may affect children diagnosed with osteosarcoma

Children diagnosed with osteosarcoma may be impacted by a DNA imprinting defect also found in parents, according to new research from the Masonic Cancer Center, University of Minnesota. DNA imprinting is a phenomenon in which just one of the two inherited genes is active while the other is present but inactive.

27 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company.

From Quest Diagnostics 27 Jan 2016

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer.

26 Jan 2016

ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

Abcodia, a commercial stage company focused on the development of proprietary tests for the early detection of cancer, today announced expanded U.S. availability of the ROCA Test.

26 Jan 2016

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.

26 Jan 2016

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers.

25 Jan 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

22 Jan 2016

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.

22 Jan 2016

Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck cancer.

22 Jan 2016

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature — a biomarker — that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery.

22 Jan 2016

CU Cancer Center study finds distinct genetic drivers of colorectal cancer in younger and older patients

A University of Colorado Cancer Center study being presented Saturday at the 2016 Genitourinary Cancers Symposium shows genetic differences between colorectal cancer (CRC) in young and old patients, possibly pointing toward different treatments and strategies in combating the young form of the disease.

22 Jan 2016

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.

21 Jan 2016

Paradigm, UnitedHealthcare sign contractual agreement for coverage of PCDx

Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients today announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx.

21 Jan 2016

Oncology News and Research

Further Reading

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

New NCCN Guidelines published for Vulvar Cancer

Velano Vascular obtains FDA clearance for modified version of novel blood draw device

DNA imprinting defect may affect children diagnosed with osteosarcoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Halozyme closes $150 million royalty-backed debt transaction

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

Palonosetron effective anti-emetic for paediatric chemotherapy patients

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Cardiovascular considerations crucial for CML TKI patients

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

CU Cancer Center study finds distinct genetic drivers of colorectal cancer in younger and older patients

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Paradigm, UnitedHealthcare sign contractual agreement for coverage of PCDx

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News